Location History:
- Maselheim, DE (1999)
- Maselheim-Sulmingen, DE (1995 - 2008)
- Maselheim/Sulmingen, DE (2002 - 2009)
Company Filing History:
Years Active: 1995-2009
Title: Gerhard Hallermayer: Innovator in Pharmaceutical Chemistry
Introduction
Gerhard Hallermayer is a notable inventor based in Maselheim-Sulmingen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of modified amino acids and their applications in medicine. With a total of 10 patents to his name, Hallermayer's work has had a profound impact on drug development and therapeutic solutions.
Latest Patents
Among his latest patents, Hallermayer has developed modified amino acids and pharmaceuticals containing these compounds. His invention relates to modified amino acids of a general formula, which includes their tautomers, diastereomers, enantiomers, and mixtures thereof. These compounds are particularly useful in the production and purification of antibodies and serve as diagnostic aids in neurotransmitter research. Another significant patent involves cyclopropane CGRP antagonists, which possess valuable pharmacological properties, particularly CGRP-antagonistic properties. This patent outlines the pharmaceutical compositions containing these compounds and the processes for their preparation.
Career Highlights
Throughout his career, Hallermayer has worked with prominent companies in the pharmaceutical industry, including Dr. Karl Thomae GmbH and Karl Thomae GmbH. His experience in these organizations has allowed him to refine his expertise in drug formulation and development.
Collaborations
Hallermayer has collaborated with notable colleagues such as Klaus Rudolf and Wolfgang Eberlein. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Gerhard Hallermayer's innovative work in pharmaceutical chemistry has led to significant advancements in the field. His contributions through various patents demonstrate his commitment to improving medical treatments and enhancing drug efficacy.